- 2-MeA
- 2-Methylamphetamine
- 2-Me-AMP
- Ortetamine
- oTAP
Higgs, RA; Glennon, RA. Stimulus properties of ring-methyl amphetamine analogs. Pharmacol. Biochem. Behav., 1 Dec 1990, 37 (4), 835–837. 238 kB. https://doi.org/10.1016/0091-3057(90)90571-X #oTAP
Davis, S; Blakey, K; Rands-Trevor, K. GC-MS and GC-IRD analysis of 2-, 3- and 4-methylmethamphetamine and 2-, 3- and 4-methylamphetamine. Forensic Sci. Int., 10 Jul 2012, 220 (1–3), 67–73. 1.2 MB. https://doi.org/10.1016/j.forsciint.2012.01.028 #4 GC,MS,IR
Bailey, K; Legault, D. Analysis of the 13C-NMR spectra of mono- and dimethylamphetamines. Anal. Chim. Acta, 1 Jan 1981, 123, 75–82. 654 kB. https://doi.org/10.1016/S0003-2670(01)83160-3 #2 NMR
Shulgin, AT. Psychotomimetic drugs: structure-activity relationships. In Handbook of Psychopharmacology: Stimulants; Iversen, LL; Iversen, SD; Snyder, SH, Eds., Plenum Press, New York, 1 Jan 1978; pp 243–333. 2.6 MB. https://doi.org/10.1007/978-1-4757-0510-2_6 #65 Rhodium.
Power, JD; Clarke, K; McDermott, SD; McGlynn, P; Barry, M; White, C; O’Brien, J; Kavanagh, P. The identification of 4-methylamphetamine and its synthesis by-products in forensic samples. Forensic Sci. Int., 10 May 2013, 228 (1–3), 115–131. 1.9 MB. https://doi.org/10.1016/j.forsciint.2013.02.039 #1 GC,MS,NMR,IR
Bailey, K; Beckstead, HD; Legault, D; Verner, D. Identification of 2-, 3-, and 4-methoxyamphetamines and 2-, 3-, and 4-methylamphetamines. J. Assoc. Off. Anal. Chem., , 57 (5), 1134–1143. 2.6 MB. #IB GC,LC,MS,NMR,IR,UV,TLC
Glennon, RA. Bath salts, mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention. Adv. Pharmacol., 1 Jan 2014, 69, 581–620. 564 kB. https://doi.org/10.1016/B978-0-12-420118-7.00015-9
Welter-Luedeke, J; Maurer, HH. New psychoactive substances: chemistry, pharmacology, metabolism, and detectability of amphetamine derivatives with modified ring systems. Ther. Drug Monit., 1 Feb 2016, 38 (1), 4–11. 216 kB. https://doi.org/10.1097/FTD.0000000000000240
Segawa, H; Iwata, YT; Yamamuro, T; Kuwayama, K; Tsujikawa, K; Kanamori, T; Inoue, H. Differentiation of ring-substituted regioisomers of amphetamine and methamphetamine by supercritical fluid chromatography: Differentiation of ring-substituted regioisomers by supercritical fluid chromatography. Drug Test. Anal., 1 Mar 2017, 9 (3), 389-398. 1.3 MB. https://doi.org/10.1002/dta.2040
Hyperlab. Hyperlab new compounds. 29 Sep 2014. 232 kB. Note: Contains links to hyperlab.info that require elevated access/karma to follow.
Nichols, DE. Medicinal chemistry and structure-activity relationships. In Amphetamine and its Analogs; Cho, AK; Segal, DS, Eds., Academic Press, San Diego, CA, 1 Jan 1994; pp 3–41. 8.1 MB. #2
EMCDDA. New drugs in Europe, 2017, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Aug 2017. 672 kB. #24
Okamoto, K; Akimoto, S; Ando, T; Ikeda, Y; Kurashima, N. Differentiation of regioisomeric analogs of controlled substances using GC-IR. JCCL, 1 Oct 2016, (56), 49–70. 4.5 MB. #2-Methylamphetamine Japanese, English abstract GC,MS,IR
Clancy, L; Philp, M; Shimmon, R; Fu, S. Development and validation of a color spot test method for the presumptive detection of 25-NBOMe compounds. Drug Test. Anal., 19 Aug 2020, 13 (5), 929-943. 11.3 MB. https://doi.org/10.1002/dta.2905 #2-methylamphetamine (oretamine)
Åstrand, A; Guerrieri, D; Vikingsson, S; Kronstrand, R; Green, H. In vitro characterization of new psychoactive substances at the μ-opioid, CB1, 5HT1A, and 5-HT2A receptors—On-target receptor potency and efficacy, and off-target effects. Forensic Sci. Int., 1 Dec 2020, 317, 110553. 1.7 MB. https://doi.org/10.1016/j.forsciint.2020.110553 #2-methylamphetamine
Benington, F; Morin, RD. The chemorelease of norepinephrine from mouse hearts by substituted amphetamines. J. Med. Chem., 1 Jul 1968, 11 (4), 896–897. 244 kB. https://doi.org/10.1021/jm00310a048 #2.15